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Abstract 
Young injecting drug users are a particularly vulnerable group for Hepatitis C (HCV) 
infection. One method for minimising the risk of contraction of HCV for amphetamine users 
(not widely explored in the research to date) is through encouraging non-injecting routes of 
administration (ROA). Self-report data from 150 young injecting amphetamine users was 
analysed to investigate the influence of HCV threat on the decision to cease injecting and the 
worth of promoting the use of non-injecting ROA. Application of the Transtheoretical Model 
of Behaviour Change and the Expanded Health Belief Model showed that threat of HCV was 
not perceived as reason to cease injecting at any stage in the injecting career. Cessation was a 
result of personal choice, rather than response to any type of threat. This supports the 
promotion of harm minimisation rather than abstinence campaigns. Furthermore, the deficits 
in knowledge of HCV threat are worthy of campaign attention. 
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The threat of hepatitis C as an influence on injecting amphetamine users’ change towards 
non-injecting 
The hepatitis C virus (HCV) is a widespread, easily transmissible, blood-borne virus 
with serious and potentially fatal health consequences for the infected individual (Ryder & 
Beckingham, 2001). Furthermore, HCV positive individuals are of extremely high 
transmission risk to others and are likely to be so for a substantially long period of time 
(MacDonald et al., 2000). There is overwhelming agreement that young injecting drug users 
(i.e., those in their adolescent years or early twenties) are a particularly vulnerable group for 
HCV infection during the course of their drug using career (e.g., Carruthers & Loxley, 1995; 
Diax et al., 2001; Johnson, 2001; Loxley & Davidson, 1998; MacDonald et al., 2000; 
National Centre in HIV Epidemiology and Clinical Research, 2001). This is of particular 
importance given that the age of illicit drug initiation is decreasing, resulting in increasing 
numbers of young injecting drug users (IDU) (Degenhardt, Lynskey & Hall, 2000). 
Longer duration of injecting career is widely cited as a prominent HCV risk factor for 
two reasons. First, there is the increased likelihood of viral exposure with more injecting 
occasions (Carruthers, Lowley, Phillips & Bevan, 1997; Crofts, Aitken & Kaldor, 1999; Diaz 
et al., 2001; Hope et al., 2001; Kwiatkowski, Corsi & Booth, 2002; Steffen, Blättler, 
Gutzwiller & Zwahlen, 2001). Second, there is a general consensus that young IDU are more 
prone to risk taking in the form of needle sharing and other unsafe injecting practices (e.g., 
Crosby, 1996; Loxley, 1998) regardless of whether they have adequate knowledge of what 
constitutes disease risk (Booth, Zhang & Kwiatkowski, 1999; Carruthers & Loxley, 1995; 
Crofts & Louie, 1996).  
In Queensland, young IDU are typically amphetamine users. After cannabis, 
amphetamines are the most frequently used illicit substance by this cohort (Darke, Ross, 
Hando, Hall & Degenhardt, 2000). The 2001 National Drug Strategy Household Survey 
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indicates the number of amphetamine users is increasing (Australian Institute of Health and 
Welfare, 2002). Given the apparent unsafe injecting practices of young IDU (e.g., Crosby, 
1996; Loxley, 1998), the nature of amphetamine use is important. Compared to heroin, 
amphetamine use is often recreational (Loxley, 1997) and occurs in social situations, such 
night clubbing (Kanieniecki, Vincent, Allsop, & Lintzeris, 1998). Thus users are more likely 
to be around others when they administer the drug (Darke et al., 2000) and in a context for 
sharing injecting equipment.  
Reducing HCV risk for injecting drug users  
Loxley (1998) describes the following hierarchy of recommendations for drug users, 
aimed at HIV/AIDS prevention: (1) avoid using drugs; (2) if you do use, avoid injection; (3) 
if you do inject, do not share needles; (4) if sharing is unavoidable, sterilise needles with 
bleach1. These objectives are arguably relevant to HCV risk reduction also and are widely 
cited in the literature as being the primary HCV prevention options (e.g., Lowe & Cotton, 
1999).  
While much research and public health campaign attention has addressed Loxley’s 
(1998) first, third and fourth objectives, relatively little research and policy attention has been 
given to Loxley’s second objective, that is, the promotion of drug consumption via routes of 
administration (ROA) other than injecting. This practice would seem particularly relevant to 
HCV prevention as it would eliminate the risk of viral contact from all injection equipment, a 
risk factor which injectors who do not share needles per se, may not be aware (Hagan, Thiede, 
Weiss & Hopkins, 2001). Furthermore, aside from disease risk, a multitude of detrimental 
effects of injecting drug use exist (Gossop, Marsden, Stewart & Treacy, 2000). These include 
increased addiction, due to higher potency of the ingested substance as well as more rapid 
delivery to the brain (Gossop et al., 2000); problematic behaviours (e.g., involvement in 
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crime); and a range of severe psychological symptoms, such as psychosis (Hall & Hando, 
1996).   
Lowe and Cotton (1999) reviewed Australia’s response to the HCV epidemic and 
recommend that information on non-injecting ROA should be made available and that 
equipment should be provided to facilitate these (see also Carruthers et al., 1997). Despite 
these claims, it appears that implementing such changes may be extremely difficult and 
effective change is far more complex than simply promoting different practices and educating 
drug users about specific disease risk behaviours. Further investigation into the worth of 
promoting the use of alternate ROA as a harm minimisation strategy is clearly warranted by 
the extent of the amphetamine problem (particularly amongst youth, a high HCV risk group), 
the drug-specific risk factors to intravenous users and the existence of alternative means of 
administration2.  
Models of health behaviours and behaviour change  
It is widely recommended that the planning and implementation of health strategies 
must be informed by theoretically developed models of behaviour. The dangers of 
implementing public health strategies based on assumptions rather than validated models is 
evident in poorly planned, early AIDS prevention campaigns (see Fishbein & Guinan, 1996). 
In many countries, the approach was to focus largely on the provision of information on 
disease transmission and avoidance. Based on an extensive review of these campaigns, 
Fishbein and Guinan (1996) argue that information provision does not necessarily equate with 
behaviour change or preventative action. 
With regard to unsafe injecting of illicit drugs (such as sharing needles and syringes), 
research to date appears to generally focus on knowledge of AIDS/HIV risk and adherence to 
dangerous practice. No research (known to the authors) applies such models exclusively to 
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HCV prevention, or to the transition from injecting to non-injecting drug use as a means of 
HCV (or HIV/AIDS) exposure avoidance. 
Expanded Health Belief Model. Two popular health behaviour change models are the 
Expanded Health Belief Model (EHBM) and the Transtheoretical Model of Behaviour 
Change (TMBC). The EHBM is based on the Health Belief Model (HBM: Rosenstock, 1966; 
Janz & Becker, 1984). The HBM states that health promoting behaviours are practiced when 
there is a belief that a health threat exists (Booth et al., 1999). Specifically, the model 
proposes that the factors that influence health behaviour include the value an individual places 
on their own health, their specific beliefs about vulnerability (e.g., I use needles, therefore I 
could get HCV) and their understanding of the severity and consequences of the health threat 
(Booth et al., 1999). The HBM also holds that individuals desire good health more than they 
desire the problem behaviour and that the individual must believe that a specific behaviour (or 
set of behaviours) will be effective in risk reduction (response efficacy), e.g., if I do not inject, 
I cannot get HCV. Finally, the EHBM includes self-efficacy. Borrowed from Bandura’s social 
cognitive theory, self-efficacy refers to the perception that one has the ability to implement 
change under the circumstances that prevail (Fishbein & Guinan, 1996). The HBM, its 
expanded version and various combinations of these have been widely applied as explanatory 
models of the practicing of health behaviours, as well as the basis for development and 
scrutiny of health promotional campaigns (Jayanti & Burns, 1998; Mattson, 1999).  
Transtheoretical Model of Behaviour Change. The TMBC (Prochaska & DiClemente, 
1986; DiClemente & Prochaska, 1998) identifies stages of readiness to change and proposes 
that treatment approaches are stage-specific in their effectiveness and must be applied as such 
(DiClemente, 1993; Heather & Rollnick, 1993). There are three stages of change (SOC) that 
are assessed as apart of an individual’s readiness to change3. These are precontemplation 
(whereby there is no intention to modify the behaviour (DiClemente, 1993; Van Duyn, 
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Heimendinger, Russek-Cohen & DiClemente, 1998)), contemplation (where the individual 
may think about changing the behaviour but feels unable to take action (DiClemente, 1993; 
Norman, Velicer, Fava & Prochaska, 1998)), and action (where the individual is actively and 
effectively changing the behaviour (Van Duyn et al., 1998)). 
The TMBC has been successfully applied to a wide range of health acquisition 
behaviours, for example good nutrition, exercise, sunscreen use and breast cancer screening 
(Prochaska et al., 1994). It has also been applied in the reduction of addictive behaviours such 
as alcoholism (Heather & Rollnick, 1993), smoking and other substance abuse (Prochaska et 
al., 1994) as well as HIV risk behaviours (Stevens & Estrada, 1996).  
DiClemente (1999) claims that there is considerable evidence that identifying TMBC 
stage specific characteristics of those with addictive behaviours can provide valuable 
information to be used for individual interventions. With regard to illicit drug harm 
minimisation and HCV prevention, modification of the behaviour towards non-injecting ROA 
is a possible option, particularly where cessation of drug use is not yet achievable. However, 
no research has been found that investigates the worth of application of the TMBC in the 
context of SOC towards giving up injecting (but not necessarily ceasing use of the substance). 
The value of applying this model in this context lies in determining whether drug injectors fit 
the stage criteria regarding changing to non-injecting ROA. Furthermore a description of 
characteristics of those in each stage is warranted for intervention strategies.  
Aims of the study 
This study aims to identify a stage towards non-injecting (according to the TMBC) 
relevant to each intravenous amphetamine user from the sample. Each participant will be 
categorised as being in the precontemplation, contemplation or action stage in respect to 
change towards abstinence from injecting use. The second aim of this study is to investigate 
which of the EHBM constructs are influential at each SOC, that is, to identify beliefs that are, 
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according to this model, prerequisites to change towards non-injecting. For the purpose of this 
research, the six constructs of the EHBM used are as follows: general health values, beliefs 
about HCV vulnerability, beliefs about HCV severity, belief that ceasing injecting is an 
effective measure to combat HCV threat, belief that the benefits of non-injecting exceed the 
costs of giving up injecting and self-efficacy (belief that one is capable of giving up 
injecting). Finally, this study will describe potential reasons that IDU consider valid to cease 
injecting. 
Method 
Participants 
One hundred and fifty IDU (86 male, 63 female and one transgender) participated in the 
current study. Inclusion criteria were: being aged between 16 and 25 (mean age = 21.6 years); 
having last injected amphetamine no longer than 6 months ago; and having first injected any 
drug no longer than 4 years ago. Respondents were living in or around Brisbane, the Gold 
Coast, Toowoomba and Caboolture.  
Materials 
An extensive, structured questionnaire was used to gain self-report data. This instrument 
targeted socio-demographic circumstances and drug use and injecting trends. Virus status 
items were also included, as were items to measure the influence of HCV threat on the 
cessation of injecting. Items examining individuals’ SOC classification towards non-injecting 
and the influence of variables of the EHBM in the context of HCV threat were included.  
SOC towards non-injecting. Heather and Rollnick’s (1993) Readiness to Change 
Questionnaire (to classify problem drinkers’ SOC towards abstinence from alcohol 
consumption) was adapted to categorise SOC applicable to intravenous amphetamine users’ 
movement towards abstinence from amphetamine use or sole use of ROA other than injecting. 
Statements were re-worded to apply to injecting. For example, Heather and Rollnick’s (1993) 
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item, “my drinking is a problem sometimes” was altered to “injecting causes me problems 
sometimes” for this study. Participants indicate their level of agreement with twelve 
statements on a five-point Likert scale from strongly disagree to strongly agree.  
The questionnaire comprises three subscales of four items each, which form three of the 
SOC (i.e., precontemplation, contemplation or action). Scores are summed for each subscale. 
The weighting of these three totals relative to each other determine categorisation to the 
precontemplation, contemplation or action SOC.  
Expanded health belief model. Six constructs of the EHBM were measured, each with a 
single item using a Likert scale format. Negatively worded items were recoded, so for each 
construct, a score of five indicated strong agreement with that statement (belief).  These 
statements were based on those used in the literature (e.g., Mirotznik, 1998; Neff & Crawford, 
1998; Wdowak, Kendall, Harris, & Auld, 2001). 
Procedure 
A peer researcher program was used to access the sample. This method of data 
collection has previously been effectively employed in research involving drug users (e.g., 
Crofts & Louie, 1996). In addition, the reliability of self-report data may be enhanced by this 
method due to the absence of an authoritarian relationship between interviewer and 
respondent (Kosten, Rounsaville & Kleber, 1987) and through the development of trust as the 
interviewer is also involved in the illicit behaviour (Atkinson & Flint, 2001).  
Nine interviewers were recruited from the target group via advertising at youth services 
in Brisbane and surrounding areas. The majority of the interviewers worked for such services 
or needle exchanges and all had injecting drug experience themselves. Peer researchers were 
paid $20 per questionnaire administered.  
Advertising for project participation was distributed at needle exchanges, in street press 
magazines and at rave parties. A snowballing method of data collection, whereby researchers 
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interview people they know and ask participants to refer acquaintances to the researcher, was 
also encouraged. This method of data collection is readily used for accessing drug users for 
research (e.g., Carruthers, Loxley, Phillips & Bevan, 1996) due to the social stigma associated 
with illicit drug use (Atkinson & Flint, 2001). It was thought that the snowballing method 
would be particularly advantageous as the sample would be more likely include IDU who do 
not frequent needle exchanges (where participation advertising was posted) and, therefore, do 
not access the safe injecting information provided at these organisations4. 
Initial contact was made either by participants calling an advertised project phone 
number or through researchers following up information given during snowballing. 
Researchers met with participants at convenient locations as arranged, such as homes, youth 
services or cafés. Importantly, prior to questionnaire administration, matters of confidentiality 
and anonymity were stressed, due to the sensitive, illegal nature of the behaviour being 
studied and the association of paranoia with amphetamine use (Davey & Davies, 1999). 
Interviews were of approximately 45 minutes duration. Self-report data was obtained using a 
structured interview format and participants were paid $20. Researchers sealed completed 
questionnaires in envelopes and returned them to project organisers.  
Results 
Data analysis  
Analyses were undertaken using the Statistical Package for Social Sciences (SPSS) 
version 10. All analyses were evaluated at an alpha level of .05, unless otherwise stated. 
Perusal of the data revealed nine participants who reported injecting for five years or longer 
and who therefore did not meet inclusion criteria for the study; these participants were 
excluded from analyses on this basis. For the purpose of determining the influence of HCV 
threat on drug users’ decisions to stop injecting at each SOC, the data of those respondents 
who had stated they were HCV positive was also excluded from further analysis (n = 22)5.  
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Characteristics of the sample (N = 119) 
The mean age of initiation into drug injecting was 18.74 years (SD = 2.56 years). For 
87.3% of the sample, the first drug they reported injecting was amphetamine. The majority of 
these users had used amphetamine some way other than injecting prior to the first injecting 
occasion (71.8%, n = 74). Heroin was the first drug injected by 10.2% of the sample and 
cocaine and ecstasy were each the first injecting drug of one respondent. The mean duration 
of injecting career was 2.69 years (SD = 1.28 years). For 89.9% of the sample, amphetamine 
was the preferred injecting drug. Heroin was the preferred injecting drug of 8.4% of the 
sample and two respondents preferred cocaine. Less than half of respondents considered 
themselves dependent on one or more types of drugs (48.7%).  
 SOC classification was determined using the quick method of stage allocation from 
Heather and Rollnick’s Readiness to Change questionnaire (1993). Of the current sample, 24 
were classified as precontemplation, 73 as contemplation and 21 as action.  
Stage of change towards non-injecting as influenced by constructs of the EHBM  
One-way ANOVAs were conducted to determine whether there were any significant 
differences between the three SOC groups’ scores on each construct of the EHBM. Post-hoc 
analyses were conducted using Dunnett’s C. 
 
 
Table 1 shows the mean values and standard deviations of each EHBM variable for 
each SOC group. For the first EHBM construct, general health values, the ANOVA was not 
significant F(2,115) = .050, p>.05. Examination of the descriptive statistics for this variable 
showed that, on average, participants held this belief (as indicated by mean scores of greater 
than 4). 
Insert Table 1 about here 
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For the second EHBM construct, beliefs about HCV vulnerability, there were no 
significant differences between the groups F(2,115) = 1.937, p>.05. As no group scored 
greater than 4 on this construct, this indicated that it was not a belief held by any SOC group. 
For the third EHBM construct, beliefs about HCV severity, there were no significant 
differences in scores F(2,116) = .895, p>.05. The mean values for all the SOC groups on this 
variable indicated that this belief was held by all of the groups. 
For the fourth EHBM construct, belief that ceasing injecting is effective to combat HCV 
threat, the ANOVA revealed no differences between the groups F(2, 114) = .505, p>.05. All 
groups averaged a score of less than 4 on this variable. 
For the fifth EHBM construct, that the benefits of ceasing injecting outweigh costs of 
cessation, there were no significant differences, F(2, 116) = .395, p>.05. No group averaged 
more than 4 on this variable. However, there was a trend for the precontemplation group of 
IDU to hold this belief (mean score greater than 3), while the contemplation and action groups 
tended not to hold that belief (mean score less than 3). 
For the sixth EHBM variable, self-efficacy, there were significant differences between 
SOC groups F(2, 116) = 5.88, p = .004, η2 = .092. Post-hoc analyses revealed the action group 
scored significantly higher than the contemplation and precontemplation groups, which did 
not differ6.  
Potential reasons to cease injection 
Frequencies were calculated to examine the number of participants who endorsed 
various potential reasons to cease injecting. Only a relatively small percent of the sample 
endorsed health and disease reasons to cease injection (see Table 2). The number of young 
IDU who endorsed disease threats, including fear of HIV (15.5%) and fear of HCV (13.8%), 
as potential reasons to cease injection was particularly low. Comparatively, Table 2 shows 
that a high percentage of respondents would potentially stop injecting for reasons other than 
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disease threat. Personal choice reasons for ceasing injection such as being sick of using, 
wanting to get their act together and starting a family were strongly endorsed. Fewer 
participants endorsed various social pressures from others including peer pressure, family 
pressure, work pressure, police harassment and fear of losing one’s partner. Finally, drug 
availability was clearly influential; approximately one quarter of the respondents nominated 
injecting drugs, their source and needles becoming less available as reasons to stop injecting. 
In contrast, only six respondents cited that non-injecting drugs becoming more available 
would stop them injecting.  
 
 
In summary, none of the SOC groups held all six EHBM constructs (including the 
action group). IDU generally valued their health and perceived the severity of HCV. The 
EHBM constructs of perceived vulnerability, cessation of injection as effective to combat 
HCV threat and that the benefits outweigh the cost of cessation of injection were not 
adequately held by any SOC group. There were no differences in the level of agreement of 
each of these 5 EHBM constructs between the SOC groups. The only difference between the 
SOC groups was on self-efficacy, where the action group reported stronger agreement with 
this statement. A number of potential reasons for ceasing injection were endorsed by the 
participants.  
Discussion 
The results of this research demonstrate that young injecting amphetamine users can be 
classified into SOC according to the TMBC. These classifications may be useful in designing 
interventions to manage HCV risk. This sample of young injecting amphetamine users 
consisted primarily of IDU in the contemplation SOC (where they recognise that there are 
some positive and negative consequences of drug use). Based on this finding, perhaps broadly 
Insert Table 2 about here 
Injecting amphetamine and HCV threat 15 of 26 
administered interventions should be tailored to this SOC group to have maximum effect on 
the transmission of HCV throughout the amphetamine injecting community. 
None of the SOC groups held all six of the EHBM constructs. This is not surprising 
considering that this was a sample of amphetamine users who were selected on the basis of 
the criterion that they had injected a drug within the last six months. Regardless, the results of 
this study offer some support of the use of the EHBM with IDU, that is, the action SOC group 
held three of the six EHBM constructs whereas the other SOC groups only held two of the six 
beliefs necessary for change. Self-efficacy, the sixth EHBM construct, was the only EHBM 
construct that distinguished the three SOC groups. 
More importantly, the results indicate that HCV threat is not sufficient to result in a 
decision to cease injecting. As mentioned, even those in the action SOC did not hold all six 
constructs of the EHBM that constitute change in the context of HCV threat. While similar 
results have been reported elsewhere (e.g., Mattson, 1999), the number of EHBM beliefs not 
held by this sample was unexpectedly high. One explanation for this finding is that the use of 
a single item for each construct (whilst used to minimise the length of the questionnaire, due 
to the nature of the recruitment of the participants) may not have been an adequate measure of 
each of the EHBM constructs. However, research investigating the EHBM in another sample 
of IDU is clearly necessary to further examine the usefulness of this model. 
Inadequate beliefs regarding HCV threat in the context of IDU have implications for 
secondary prevention, harm minimisation campaigns that have been used to reduce the spread 
of this disease. Whilst there is no evidence that changing these beliefs will prompt IDU to 
cease injecting solely due to HCV threat, it is arguable that addressing these deficits can be 
advantageous for safe practice. For example, few injectors felt they were susceptible to HCV. 
Raising awareness of the ease of transmissibility of the virus may help to heighten the belief 
of personal virus susceptibility. Similarly, no SOC group reported that ceasing injecting was 
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effective to combat HCV threat. Education about other transmission paths (such as sharing 
toothbrushes) is important. However, it is clear that these young people have inadequate 
knowledge that the likelihood of contracting the virus other than through their injecting drug 
use is extremely remote, and therefore that their status as an IDU puts them at a 
disproportionately high HCV risk compared to the general population. 
Secondary prevention education can be SOC specific (DiClemente, 1999). Those beliefs 
not held can be addressed for one group and a different set addressed for another, once a 
classification is established. The current results can also be interpreted as showing which 
beliefs are adequate across SOC groups and therefore should not be prioritised for harm 
minimisation campaigns. For example, all groups valued good health (the first EHBM 
variable) and reported understanding the severity of HCV (the third EHBM variable). Thus, 
education regarding these matters is of lesser importance than providing information about 
those areas in which IDU did not endorse the beliefs. 
While it seems that cessation of injecting is unlikely to occur solely due to HCV threat, 
the current study also examined potential reasons for cessation of injection. Interestingly, 
23.3% of the sample stated they may cease injecting if injecting drugs became less available, 
yet only 5.5% endorsed ceasing injection if non-injecting drugs became more available. It 
seems that the non-injecting ROA are not as appealing as injecting, once injecting has 
commenced. Obviously, of interest is investigating why non-injecting amphetamine users 
have not progressed to injecting the drug. Such information may be useful for encouraging 
those in the wider drug using community not to begin intravenous use. This could be explored 
in future research. 
Giving further support to the EHBM results, the current study found that compared with 
other potential circumstances, HCV threat was a relatively minor influence on the decision to 
cease injection. Only 13.8% of respondents agreed they may cease injecting because of this 
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threat. It seems logical then to promote those reasons given by greater numbers of 
respondents in the interest of injecting dissuasion. It is important to note that the reasons for 
cessation that were endorsed most highly are those requiring the most subtle health campaigns 
(e.g., 36.2% cited being sick of using and wanting to get their act together/ go straight) as 
these are matters of individual decision and value change. The results demonstrate that 
cessation of injecting tends to be a personal choice, not a result of perceived health threat nor 
of another’s influence (with the exception of incarceration). This finding lends considerable 
support to the secondary prevention, harm minimisation approach to HCV prevention (rather 
than promoting abstinence from injecting). 
In summary, the threat of HCV on its own is not enough to deter injecting once 
injecting has commenced. Therefore HCV avoidance campaigns should focus on harm 
minimisation, rather than attempting to persuade abstinence from injecting. To reinforce this 
argument, it was shown that cessation of injecting is a personal choice, and is unlikely to be a 
decision based on persuasion. Harm minimisation campaigns should be based on research. 
For example, the deficits shown in HCV threat beliefs (according to the EHBM) should be 
addressed for those in SOC groups that show such belief deficits. Similarly, where this model 
shows EHBM beliefs are held, lesser priority should be given for harm minimisation. In terms 
of HCV prevention, the promotion of non-injecting ROA for amphetamine users is likely to 
only be worthwhile for certain groups. Injecting amphetamine users who have chosen to stop 
injecting may continue use of other ROA. It is highly unlikely that those who have not made 
the decision to cease injecting could be persuaded to use other ROA instead. In terms of harm 
minimisation efforts, the greatest priority for this type of intervention is to encourage those 
amphetamine users who have not yet injected the drug not to inject, because once they have, it 
seems unlikely they will return to using other ROA.  
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Table 1.  
Mean score and Standard Deviations of EHBM Constructs for each SOC towards Non-
injecting (N = 119) 
Precontemplation Contemplation Action 
EHBM variable 
M SD M SD M SD 
General health values 4.29* .75 4.27* .82 4.33* .48 
HCV vulnerability 1.83 .98 2.26 1.24 1.86 .65 
HCV severity 4.13* .99 4.07* 1.10 4.43* .98 
Ceasing IDU effective to 
combat HCV threat 
2.79 1.1 2.53 1.17 2.52 1.12 
Benefit of ceasing IDU 
greater than costs  
3.17 1.27 2.74 1.29 2.81 1.47 
Self efficacy 3.63 1.21 3.35 1.34 4.38* .59 
Note. An asterisk (*) indicates a value greater than 4, demonstrating the belief is held and 
therefore it is an EHBM variable that should influence change. 
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Table 2.  
Reasons for Current or Possible Future Decision to Cease Injecting Drug Use 
Reason for IDU cessation n % Reason for IDU cessation n % 
Sick of using 42 36.2 Police harassment 17 14.8 
Getting act together/ going 
straight  42 36.2 Family pressure 16 14.0 
Went to jail 39 33.6 Fear of HCV 16 13.8 
Source dried up 36 31.0 Lack of needles 15 12.9 
Pregnant/start family 34 29.3 Fear of losing partner 15 12.9 
Overdose 33 28.4 Work pressure 13 11.2 
Drug related death of friend 33 28.4 Something happened to child 11 9.5 
Other health reasons  32 27.6 Peer pressure 11 9.5 
Injecting drugs became less 
available  27 23.3 Under no circumstances 10 8.6 
Financial pressure 23 19.8 Pending court case 10 8.6 
Partner wanted to stop 20 17.2 Younger sibling started injecting  8 6.9 
Fear of HIV/AIDS 18 15.5 Non-injecting drugs became more available 6 5.5 
Note. Total % may not equal 100, as multiple responses were possible. 
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Footnotes 
1. In the context of HCV risk reduction, the fourth guideline should be extended to include the 
non-sharing or bleaching of equipment other than needles (due to the greater transmissibility 
of this virus in comparison to HIV/AIDS). 
2.  Note that due to the variety of ROA available to amphetamine users, this is a suitable drug 
to encourage users to engage in ROA other than injecting. 
3.  The TMBC has five SOC: precontemplation, contemplation, preparation, action and 
maintenance. However, in order to classify all participants the quick method of stage 
allocation is used, which only assesses the three SOC (Heather & Rollnick, 1993). 
4.  This group may represent a significant proportion of the drug injecting population. In a 
sample of IDU, Lennings and Pritchard (1999) found that 66% obtained needles and syringes 
from pharmacies only, rather than needle exchanges. 
5.  These participants may perceive a lesser threat of HCV. Although a HCV positive drug 
user faces the risk of infection with more than one strand of the disease (Watson, 2000), many 
users are not aware of this risk. Consequently, the beliefs of this group may mask the 
influence of this threat on injecting behaviour. 
6.  Due to the nature of the sample, i.e., injecting amphetamine users who are engaging in an 
addictive behaviour, it was believed the sixth EHBM construct (self-efficacy) may be affected 
by the IDU perceived dependency on the substance. Therefore this ANOVA was re-run with 
perceived dependency as a covariate. Results for this ANOVA were, F(2, 115) = 6.355, p = 
.002, η² = .01. 
 
